These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 28695755

  • 1. Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations.
    Damlaj M, Al Balwi M, Al Mugairi AM.
    Leuk Lymphoma; 2018 Mar; 59(3):739-742. PubMed ID: 28695755
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia.
    Oka S, Ono K, Nohgawa M.
    Invest New Drugs; 2020 Oct; 38(5):1598-1600. PubMed ID: 31965420
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.
    Gordon MJ, Raess PW, Young K, Spurgeon SEF, Danilov AV.
    Br J Haematol; 2017 Nov; 179(3):501-503. PubMed ID: 27391978
    [No Abstract] [Full Text] [Related]

  • 10. Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia.
    Eyre TA, Fox CP, Shankara P, Went R, Schuh AH.
    Br J Haematol; 2017 May; 177(3):486-491. PubMed ID: 27061924
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. T-cell prolymphocytic leukemia frequently shows cutaneous involvement and is associated with gains of MYC, loss of ATM, and TCL1A rearrangement.
    Hsi AC, Robirds DH, Luo J, Kreisel FH, Frater JL, Nguyen TT.
    Am J Surg Pathol; 2014 Nov; 38(11):1468-83. PubMed ID: 25310835
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
    Collignon A, Wanquet A, Maitre E, Cornet E, Troussard X, Aurran-Schleinitz T.
    Curr Oncol Rep; 2017 Apr; 19(4):29. PubMed ID: 28324286
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.